Slideshow

Impact of Canagliflozin on Renoprotection in T2DM

Author(s):

Veronica Hackethal MD

Will SGLT2 inhibitor canagliflozin prove renoprotective in T2DM patients? CANVAS study authors sought to find out.

Related Videos
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Related Content
Dhruv Kazi, MD | Credit: PCSK9 Forum
November 18th 2024

More than 50% of US Adults Considered Eligible for Semaglutide with Current Labeling

Patrick Campbell
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
10-Year Follow-Up Shows Lasting Benefits of Bariatric Surgery for Teens with Severe Obesity
October 30th 2024

10-Year Follow-Up Shows Lasting Benefits of Bariatric Surgery for Teens with Severe Obesity

Chelsie Derman
Diabetes Dialogue: Diabetes Tech Updates in October 2024
November 11th 2024

Diabetes Dialogue: Diabetes Tech Updates in October 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
SGLT2i Outperforms DPP4i in Improving Hepatic Fibrosis Indices in T2D, MASLD| Image Credit: Markus Spiske/Unsplash
October 15th 2024

SGLT2i Outperforms DPP4i in Improving Hepatic Fibrosis Indices in MASLD

Connor Iapoce
HCPLive Endocrinology Month in Review September 2024 thumbnail
October 6th 2024

Endocrinology Month in Review: September 2024

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.